NASDAQ · ONTX
Healthcare · Biotechnology
$7.29
Down-$1.22 (-16.76%)
Updated Nov 4, 2026, 7:09 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ONTX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
ONTX closed at $7.29 after 21 trading sessions, down 61.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $7.14 | $7.65 | $7.14 | $7.292 | 7.84K |
| Nov 2, 2026 | $7.34 | $7.38 | $6.56 | $6.5723 | 6.98K |
| Oct 30, 2026 | $7.13 | $7.71 | $6.91 | $7.2684 | 26.66K |
| Oct 29, 2026 | $9.35 | $9.36 | $8.80 | $8.96 | 10.94K |
| Oct 28, 2026 | $8.715 | $9.20 | $8.68 | $9.17 | 18.71K |
| Oct 27, 2026 | $8.06 | $8.51 | $7.9986 | $8.3654 | 2.04K |
| Oct 26, 2026 | $7.26 | $7.90 | $7.195 | $7.51 | 144.59K |
| Oct 23, 2026 | $7.235 | $7.74 | $7.07 | $7.1807 | 245K |
| Oct 22, 2026 | $8.51 | $8.51 | $7.20 | $7.2099 | 32.07K |
| Oct 21, 2026 | $9.5641 | $9.5641 | $9.04 | $9.1356 | 2.64K |
| Oct 20, 2026 | $9.00 | $9.26 | $8.59 | $8.9715 | 5.57K |
| Oct 19, 2026 | $10.11 | $10.22 | $9.46 | $9.46 | 11.92K |
| Oct 16, 2026 | $9.75 | $9.75 | $9.0862 | $9.0862 | 6.14K |
| Oct 15, 2026 | $9.69 | $10.26 | $9.2095 | $10.26 | 18.82K |
| Oct 14, 2026 | $12.075 | $12.075 | $10.575 | $10.98 | 17.87K |
| Oct 13, 2026 | $13.18 | $13.1999 | $12.47 | $13.11 | 9.47K |
| Oct 12, 2026 | $14.40 | $14.8583 | $14.1095 | $14.1095 | 2.75K |
| Oct 9, 2026 | $17.87 | $17.87 | $16.2601 | $16.4851 | 2.78K |
| Oct 8, 2026 | $16.855 | $16.855 | $15.822 | $16.2652 | 3.14K |
| Oct 7, 2026 | $17.59 | $17.775 | $16.801 | $17.6175 | 5.43K |
| Oct 6, 2026 | $20.27 | $20.2701 | $18.65 | $18.90 | 7.92K |
The latest Smart Investors Daily articles mentioning ONTX.
Company
Market Activity
Research & News
ONTX research
Company profile and research snapshot.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2023 | HC Wainwright & Co. | Buy | — |
| Aug 11, 2023 | HC Wainwright & Co. | Buy | — |
| Jun 14, 2023 | HC Wainwright & Co. | Buy | — |
| Jun 6, 2023 | HC Wainwright & Co. | Buy | — |
| May 25, 2023 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Apr 2, 2024
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the “Merger”).
GlobeNewswire Inc. · Mar 8, 2024
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
GlobeNewswire Inc. · Dec 8, 2023
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
GlobeNewswire Inc. · Nov 28, 2023
Onconova presenting at NobleCon19 Dec 4-5 in Boca Raton, FL
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ONTX.
No results
No recent SID articles mention ONTX.
